Newborn Screening

NADP+ is reduced by glucose-6-phosphate dehydrogenase enzyme (G-6-PD) in the presence of glucose-6-phosphate, and the rate of formation of NADPH is proportional to the G-6-PD activity, and is determined fluorometrically.

It is an enzymatic method for the quantitative determination of glucose-6-phosphate dehydrogenase activity from dried blood spots, with fluorometric detection.

Other Details:

• Neonatal G6PD, 5 solid plates (96) 480 wells  6199 861 
• Neonatal G6PD, 10 solid plates (96) 960 wells  6199 860

Benefits:

• Excellent reproducibility
• Superior agreement with external quality samples 
• Good stability

In a 5 year study in Brazil over 285 000 neonates were screened with Labsystems Diagnostics' Neonatal Toxoplasma gondii IgM FEIA and the prevalence was found to be 1/1867.

Fluorometric enzyme immunoassay for the determination of IgM antibodies to Toxoplasma gondii from dried blood spots. This is the first Neonatal Toxoplasma screening test in the world.

Benefits:

• First Neonatal Toxoplasma screening test in the world
• Quantitative results
• Clinically proven performance
• High sensitive ??-capture test

As a first in the world achievement, Labsystems Diagnostics has established a methodology to measure OTC, CPS1 and NAGS deficiencies on dried blood spot along with the traditional detection of ASS, ASL and ARG1 enzyme deficiencies. NeoMass AAAC for tandem MS will therefore enable detection of all urea cycle abnormalities.

Patented innovation by Labsystems Diagnostics: NeoMass AAAC innovation enables detection of all urea cycle deficiencies, including proximal abnormalities along with classical distal deficiencies measurements.

The urea cycle is a metabolic pathway occurring in the liver and kidney. Ammonia, a product of protein metabolism, is removed from circulating blood through urea cycle by conversion into urea and its elimination in urine. Urea Cycle Disorders (UCD) occurs in some inborn errors of metabolism, resulting in accumulation of nitrogenous waste which leads to vomiting, increasing lethargy, seizures, hypotonia, respiratory distress, coma, and to death if untreated. Protein restriction is the mainstay of therapy for the management of urea cycle defects.

Unique Properties of NeoMass AAAC kit – detection of OTC, CPS1 and NAGS deficiencies: Deficiencies of enzymes in the proximal part of the urea cycle have been challenging to detect in the past but the patented innovation in the new NeoMass AAAC kit changes this. As a first in the world achievement, Labsystems Diagnostics has established a methodology to measure OTC, CPS1 and NAGS deficiencies on dried blood spots along with the traditional detection of ASS, ASL and ARG1 enzyme deficiencies. NeoMass AAAC for tandem MS will therefore enable detection of all urea cycle abnormalities.

Features:

• The broadest available panel of analytes
• Easy sample preparation without derivatization
• More Analytes with less expenses
• Possibility of Automatic Sample Preparation
• 3 levels of blood spots controls - Low, Mid, High
• Unique endogenous level control
• Unraveling of Proximal & Distal Urea Cycle Disorder
• Includes Succinylacetone (SUAC) and Argininosuccinic Acid (ASA) standards
• Assay for screening more than 50 inherited metabolic disorders

• Ready-to-use kit for 960 tests
• 4 of steps: Punch, Extraction, Transfer, Injection into MS/MS
• Sample extraction without derivatization
• 4 sets of Isotope labelled internal Standards: 15 Amino Acids + 13 (Acyl) Carnitines + SUAC (Tyrosemia type-1) + ASA (Argininosuccinic Acidemia)
• 3 Dried Blood Spot Controls framing the decisional cut-off area for each of the matching internal standards
• Turnaround time for 96 samples approximately 3 hours
• High specificity and sensitivity by MS/MS detection
• Validation for multiple instrument applications
• Final concentrations calculated based on accurate peak area ratios compared to only peak intensities ratios

• Simple and easy to perform
• Excellent analytical sensitivity
• Extensive experiences from worldwide customers
• Calibrated against the latest international references

• Neonatal Phenylalanine, 10 solid plates (96), 960 wells 6199896

Revolutionary Automation in Neonatal Screening: The Labsystems Diagnostics'/ Tecan's Neonatal platform is a high throughput system intended for quantitative NS2400 AUTOMATE analysis of neonatal screening samples on 96-well microplates.

• Fully robotic platform with integrated incubator, shaker, washer, disc remover and reader
• Performs all assays - hTSH, T4, PKU, Galactose, GALT, Biotinidase, 17OHP, IRT,Toxo-IgM and G6PD
• Excellent performance and a large linear range
• High capacity - Fully loaded 25 microplates / run
• Integrated disc remover connected to the washer
• Low running costs (no disposable tips / reagent basins)
• Fully automated with hands off operations
• High sensitivity fluorometric detection
• Unique liquid handling system allows all assays to be performed on the same platform
• Top level flexibility - upgradable according to changed needs, can even be used for automatic sample preparation for other applications, such as tandem MS based screening

• 25 plates per run (NS2400)
• Reduced running costs (no disposable tips)
• Integrated disc remover
• High sensitive fluorometric detection
• Patient management software
• Highly specific
• Expandable Panels

• High throughput, less consumables, more results
• Highly sensitive fluorometric detection
• Run upto 5 Assays simultaneously
• More tools ensuring sample integrity
• No disposable tips required

• Fully integrated robotic platform with integrated incubator, shaker, washer, disc remover and reader
• Performs all assays (TSH, T4, PKU, 17OHP, G6PD, Galactose, GALT, IRT, Biotinidase & Toxo IgM)

• Comprises of wrap around card to protect samples from unwanted exposure
• Specific place for serial number and barcode sticker Specific columns to record the demographic and clinical information of the babies